TY - JOUR T1 - Early visual processing as a marker of disease, not vulnerability: Event-related potential (ERP) evidence from 22q11.2 deletion syndrome, a population at high risk for schizophrenia JF - medRxiv DO - 10.1101/2021.10.26.21265538 SP - 2021.10.26.21265538 AU - Ana A. Francisco AU - John J. Foxe AU - Douwe J. Horsthuis AU - Sophie Molholm Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/10/27/2021.10.26.21265538.abstract N2 - We investigated visual processing in 22q11.2 deletion syndrome (22q11.2DS), a condition characterized by an increased risk for schizophrenia. Visual processing differences have been described in schizophrenia but remain understudied early in the disease course. Electrophysiology was recorded during a visual adaptation task with different interstimulus intervals to investigate visual processing and adaptation in 22q11.2DS (with (22q+) and without (22q-) psychotic symptoms), compared to control and idiopathic schizophrenia groups. Analyses focused on early windows of visual processing. While increased amplitudes were observed in 22q11.2DS in an earlier time window (90-140 ms), decreased responses were seen later (165-205 ms) in schizophrenia and 22q+. 22q11.2DS, and particularly 22q-, presented increased adaptation effects. We argue that while amplitude and adaptation in the earlier time window may reflect specific neurogenetic aspects associated with a deletion in chromosome 22, amplitude in the later window may be a marker of the presence of psychosis and/or of its chronicity/severity.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported in part by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), under award number U54 HD090260. Work on rare diseases at the University of Rochester (UR) collaboration site is supported in part through the UR Intellectual and Developmental Disabilities Research Center (UR-IDDRC), which is funded by a center grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD P50 HD103536 to JJF).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board of the Albert Einstein College of Medicine gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors ER -